Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Faryal Baloch

Rheumatology Covington, GA Medical Doctor

NPI 1174519847 CMS profile 53364

1775 Access Rd, Suite C, Covington, GA 30014

Open in the dashboard

General payments

$5,747

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Faryal Baloch of Covington, GA is reported in the CMS Open Payments database as having received $5,747 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $781 35
2024 General $921 45
2023 General $749 48
2022 General $1,003 56
2021 General $1,180 74
2020 General $735 42
2019 General $379 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faryal Baloch
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Faryal Baloch were reported at $781. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Faryal Baloch Rheumatology median Middle half National median
2019 $379 $744 $153–$2,687 $163
2020 $735 $462 $98–$2,027 $114
2021 $1,180 $531 $101–$2,153 $132
2022 $1,003 $627 $125–$2,303 $149
2023 $749 $741 $145–$2,524 $160
2024 $921 $830 $166–$2,660 $164
2025 $781 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,403 122 payments
  2. Amgen Inc. $598 43 payments
  3. Janssen Biotech, Inc. $388 18 payments
  4. Pfizer Inc. $378 24 payments
  5. UCB, Inc. $282 23 payments
  6. Aurinia Pharma U.S., Inc. $218 11 payments
  7. Novartis Pharmaceuticals Corporation $187 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $167 8 payments
  9. Lilly USA, LLC $157 8 payments
  10. Sobi, Inc $149 8 payments
  11. Other $820 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,643 314 payments
  2. Education $104 7 payments
Products named General payments · program years 2019–2025
  1. RINVOQ Immunology $1,536 78 payments
  2. OFEV $383 18 payments
  3. TREMFYA $329 16 payments
  4. XELJANZ $324 21 payments
  5. Enbrel $316 25 payments
  6. SKYRIZI $305 15 payments
  7. RINVOQ Immunology $291 15 payments
  8. Cimzia $268 22 payments
  9. HUMIRA $231 13 payments
  10. COSENTYX $220 14 payments
  11. Other $2,517 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

3,396

Median for Internal Medicine: 777

Drug cost

$2,560,356

Median for Internal Medicine: $73,373

Branded share of claims

33.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 133 $987,434
Rinvoq Upadacitinib Brand 95 $594,459
Enbrel Sureclick Etanercept Brand 60 $435,770
Enbrel Mini Etanercept Brand 31 $238,628
Humira(Cf) Adalimumab Brand 19 $169,549
Benlysta Belimumab Brand 19 $98,216
Hydroxychloroquine Sulfate Generic 607 $14,223
Methotrexate Methotrexate Sodium Brand 697 $8,000
Leflunomide Generic 91 $2,923
Gabapentin Generic 169 $1,658

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$35,418

Of which drugs: $1,351

Medicare patients

132

Average age 70

Services billed

859

100 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Chronic kidney disease 33%
Depression 31%
COPD 22%
Osteoporosis 22%
Ischemic heart disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 13 390 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $273
$273 95 —
TREMFYA
  • Janssen Biotech, Inc. $189
$189 — —
XELJANZ
  • PFIZER INC. $80
$80 — —
SKYRIZI
  • AbbVie, Inc. $80
$80 — —
KINERET
  • Sobi, Inc $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record